219 related articles for article (PubMed ID: 22570294)
1. Update on safety of ESAs in cancer-induced anemia.
Glaspy J
J Natl Compr Canc Netw; 2012 May; 10(5):659-66. PubMed ID: 22570294
[TBL] [Abstract][Full Text] [Related]
2. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
[TBL] [Abstract][Full Text] [Related]
3. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials.
Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
J Cancer Res Clin Oncol; 2012 Feb; 138(2):179-87. PubMed ID: 21972052
[TBL] [Abstract][Full Text] [Related]
4. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J
Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104
[TBL] [Abstract][Full Text] [Related]
5. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
Wauters I; Vansteenkiste J
Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
[TBL] [Abstract][Full Text] [Related]
6. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
Aapro M; Spivak JL
Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-induced anemia: the story of darbepoetin alfa.
Vansteenkiste J; Wauters I; Elliott S; Glaspy J; Hedenus M
Curr Med Res Opin; 2013 Apr; 29(4):325-37. PubMed ID: 23323876
[TBL] [Abstract][Full Text] [Related]
8. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R
Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748
[TBL] [Abstract][Full Text] [Related]
9. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
10. Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents.
Mhaskar R; Djulbegovic B
JAMA Oncol; 2016 Nov; 2(11):1499-1500. PubMed ID: 27387766
[TBL] [Abstract][Full Text] [Related]
11. Management of anemia in cancer patients.
Calabrich A; Katz A
Future Oncol; 2011 Apr; 7(4):507-17. PubMed ID: 21463140
[TBL] [Abstract][Full Text] [Related]
12. Erythropoiesis-stimulating agents for anemic patients with cancer.
Sheikh S; Littlewood TJ
Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
[TBL] [Abstract][Full Text] [Related]
13. Pharmacovigilance in practice: erythropoiesis-stimulating agents.
Hedenus M; Ludwig H; Henry DH; Gasal E
Cancer Med; 2014 Oct; 3(5):1416-29. PubMed ID: 24890561
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin in cancer patients.
Glaspy JA
Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
[TBL] [Abstract][Full Text] [Related]
15. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
16. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron.
Henry DH; Dahl NV; Auerbach MA
Am J Hematol; 2012 Mar; 87(3):308-10. PubMed ID: 22262486
[TBL] [Abstract][Full Text] [Related]
17. Cancer- and chemotherapy-induced anemia.
Rodgers GM; Becker PS; Blinder M; Cella D; Chanan-Khan A; Cleeland C; Coccia PF; Djulbegovic B; Gilreath JA; Kraut EH; Matulonis UA; Millenson MM; Reinke D; Rosenthal J; Schwartz RN; Soff G; Stein RS; Vlahovic G; Weir AB
J Natl Compr Canc Netw; 2012 May; 10(5):628-53. PubMed ID: 22570293
[TBL] [Abstract][Full Text] [Related]
18. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients.
Bohlius J; Tonia T; Schwarzer G
Acta Haematol; 2011; 125(1-2):55-67. PubMed ID: 21150188
[TBL] [Abstract][Full Text] [Related]
19. Erythropoiesis-stimulating agents in oncology.
Glaspy JA
J Natl Compr Canc Netw; 2008 Jul; 6(6):565-75. PubMed ID: 18597710
[TBL] [Abstract][Full Text] [Related]
20. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.
Rizzo JD; Somerfield MR; Hagerty KL; Seidenfeld J; Bohlius J; Bennett CL; Cella DF; Djulbegovic B; Goode MJ; Jakubowski AA; Rarick MU; Regan DH; Lichtin AE; ;
J Clin Oncol; 2008 Jan; 26(1):132-49. PubMed ID: 17954713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]